TY - JOUR
T1 - A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors
AU - Pusceddu, Sara
AU - Barretta, Francesco
AU - Trama, Annalisa
AU - Botta, Laura
AU - Milione, Massimo
AU - Buzzoni, Roberto
AU - De Braud, Filippo
AU - Mazzaferro, Vincenzo
AU - Pastorino, Ugo
AU - Seregni, Ettore
AU - Mariani, Luigi
AU - Gatta, Gemma
AU - Di Bartolomeo, Maria
AU - Femia, Daniela
AU - Prinzi, Natalie
AU - Coppa, Jorgelina
AU - Panzuto, Francesco
AU - Antonuzzo, Lorenzo
AU - Bajetta, Emilio
AU - Brizzi, Maria Pia
AU - Campana, Davide
AU - Catena, Laura
AU - Comber, Harry
AU - Dwane, Fiona
AU - Fazio, Nicola
AU - Faggiano, Antongiulio
AU - Giuffrida, Dario
AU - Henau, Kris
AU - Ibrahim, Toni
AU - Marconcini, Riccardo
AU - Massironi, Sara
AU - Žakelj, Maja Primic
AU - Spada, Francesca
AU - Tafuto, Salvatore
AU - Van Eycken, Elizabeth
AU - Van der Zwan, Jan Maaten
AU - Giacomelli, Luca
AU - Žagar, Tina
AU - Miceli, Rosalba
AU - NEPscore Working Group
N1 - © 2018 The authors.
PY - 2018/6
Y1 - 2018/6
N2 - No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in three independent cohorts of patients from five different European countries, aimed to develop and validate a classification prognostic score for OS in patients with stage IV WDNETs. We retrospectively collected data on 1387 patients: (i) patients treated at the Istituto Nazionale Tumori (Milan, Italy; n = 515); (ii) European cohort of rare NET patients included in the European RARECAREnet database (n = 457); (iii) Italian multicentric cohort of pancreatic NET (pNETs) patients treated at 24 Italian institutions (n = 415). The score was developed using data from patients included in cohort (i) (training set); external validation was performed by applying the score to the data of the two independent cohorts (ii) and (iii) evaluating both calibration and discriminative ability (Harrell C statistic). We used data on age, primary tumor site, metastasis (synchronous vs metachronous), Ki-67, functional status and primary surgery to build the score, which was developed for classifying patients into three groups with differential 10-year OS: (I) favorable risk group: 10-year OS ≥70%; (II) intermediate risk group: 30% ≤ 10-year OS < 70%; (III) poor risk group: 10-year OS <30%. The Harrell C statistic was 0.661 in the training set, and 0.626 and 0.601 in the RARECAREnet and Italian multicentric validation sets, respectively. In conclusion, based on the analysis of three 'field-practice' cohorts collected in different settings, we defined and validated a prognostic score to classify patients into three groups with different long-term prognoses.
AB - No validated prognostic tool is available for predicting overall survival (OS) of patients with well-differentiated neuroendocrine tumors (WDNETs). This study, conducted in three independent cohorts of patients from five different European countries, aimed to develop and validate a classification prognostic score for OS in patients with stage IV WDNETs. We retrospectively collected data on 1387 patients: (i) patients treated at the Istituto Nazionale Tumori (Milan, Italy; n = 515); (ii) European cohort of rare NET patients included in the European RARECAREnet database (n = 457); (iii) Italian multicentric cohort of pancreatic NET (pNETs) patients treated at 24 Italian institutions (n = 415). The score was developed using data from patients included in cohort (i) (training set); external validation was performed by applying the score to the data of the two independent cohorts (ii) and (iii) evaluating both calibration and discriminative ability (Harrell C statistic). We used data on age, primary tumor site, metastasis (synchronous vs metachronous), Ki-67, functional status and primary surgery to build the score, which was developed for classifying patients into three groups with differential 10-year OS: (I) favorable risk group: 10-year OS ≥70%; (II) intermediate risk group: 30% ≤ 10-year OS < 70%; (III) poor risk group: 10-year OS <30%. The Harrell C statistic was 0.661 in the training set, and 0.626 and 0.601 in the RARECAREnet and Italian multicentric validation sets, respectively. In conclusion, based on the analysis of three 'field-practice' cohorts collected in different settings, we defined and validated a prognostic score to classify patients into three groups with different long-term prognoses.
U2 - 10.1530/ERC-17-0489
DO - 10.1530/ERC-17-0489
M3 - Article
C2 - 29559553
VL - 25
SP - 607
EP - 618
JO - Endocrine-Related Cancer
JF - Endocrine-Related Cancer
SN - 1351-0088
IS - 6
ER -